Cite
HARVARD Citation
Jiang, Z. et al. (2019). Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology. 20 (6), pp. 806-815. [Online].